title: Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer.
abstract: BACKGROUND
  Targeting BRAF V600E mutation has been proven effective in the treatment of several types of cancer. In endometrial adenocarcinoma, the BRAF V600E mutation has been rarely reported. Whether targeting BRAF oncogene may represent a plausible therapeutic strategy for the rare patients with BRAF-mutated endometrial cancer remains to be ascertained in prospective studies.
  
  
  METHODS
  We report herein the case of a heavily pre-treated patient with recurrent microsatellite instability high (MSI-H) BRAF V600E mutated endometrial adenocarcinoma, which was successfully treated with the V600E targeting agent dabrafenib. After developing resistance to this agent, the MEK targeting agent trametinib was added to dabrafenib achieving again a therapeutic response.
  
  
  CONCLUSIONS
  This case shows that dabrafenib both as monotherapy and when combined with trametinib may exert significant therapeutic activity in heavily pretreated BRAF V600E mutated endometrial adenocarcinoma, and highlight potential benefits of personalized treatment in this disease.
authors.affiliation: Drug Development Unit, Sarah Cannon Research Institute, 93 Harley Street, London, W1G 6AD UK ; University College London, London, UK.
authors.forename: Michele
authors.initials: M
authors.lastname: Moschetta
authors.affiliation: Drug Development Unit, Sarah Cannon Research Institute, 93 Harley Street, London, W1G 6AD UK ; University College London, London, UK.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Mak
authors.affiliation: Drug Development Unit, Sarah Cannon Research Institute, 93 Harley Street, London, W1G 6AD UK.
authors.forename: Joana
authors.initials: J
authors.lastname: Hauser
authors.affiliation: Drug Development Unit, Sarah Cannon Research Institute, 93 Harley Street, London, W1G 6AD UK.
authors.forename: Catriona
authors.initials: C
authors.lastname: Davies
authors.affiliation: Drug Development Unit, Sarah Cannon Research Institute, 93 Harley Street, London, W1G 6AD UK ; University College London, London, UK.
authors.forename: Mario
authors.initials: M
authors.lastname: Uccello
authors.affiliation: Drug Development Unit, Sarah Cannon Research Institute, 93 Harley Street, London, W1G 6AD UK ; University College London, London, UK.
authors.forename: Hendrik-Tobias
authors.initials: HT
authors.lastname: Arkenau
keywords: BRAF V600E mutation; Dabrafenib; Endometrial cancer; Microsatellite instability; Trametinib